La Marató de 3Cat funds two IBEC projects to improve immunotherapy in solid tumors

The La Marató de 3Cat Foundation allocates 600,000 euros to two studies from the Institute for Bioengineering of Catalonia to advance cancer treatment.

Generic image of cells and laboratory equipment.
AI

Generic image of cells and laboratory equipment.

The La Marató de 3Cat Foundation has selected two research projects from the Institute for Bioengineering of Catalonia (IBEC) to improve immunotherapy in solid tumors, with an investment of 300,000 euros for each project.

The La Marató de 3Cat Foundation has allocated 600,000 euros to two projects coordinated by researchers from the Institute for Bioengineering of Catalonia (IBEC) in its 2025 call for cancer research grants. The projects, which will run for three years, will address the difficulties immune cells face in penetrating solid tumors, a key obstacle for immunotherapy in cancers such as breast or colorectal cancer.
The 2025 edition of La Marató de 3Cat raised 4,425,548 euros, which will be allocated to 38 projects. The proposals were evaluated by 169 international experts managed by the Catalan Agency for Health Quality and Assessment (AQuAS). The two selected IBEC projects are coordinated by researchers Xavier Rovira and Xavier Trepat.
The project iNKFILTRATE, coordinated by Xavier Rovira, focuses on natural killer (NK) cells modified from induced pluripotent stem cells (iPSC). These cells will be genetically engineered to recognize the p95HER2 variant, present in some HER2-positive breast cancers, and to enhance their ability to enter and survive within the tumor environment. The research also includes in vitro and animal three-dimensional models, using spatial imaging techniques to analyze the location of NK cells within the tumor.
The second project, coordinated by Xavier Trepat in collaboration with the Cancer Research Center (CIC) of Salamanca, proposes that the mechanical properties of the tumor and internal forces hinder the entry of T lymphocytes. To test this hypothesis, "mini-guts" will be developed in organ-on-a-chip systems, combining tumor organoids with other cells to replicate tissue architecture. It will be measured how the physical environment of the tumor influences T cell migration and cytotoxic capacity.
Based on information from the official source: Parc Científic de Barcelona (18/11/2026)